Celltrion Signs Supply Contract for Truxima Worth 21 Billion KRW
[Asia Economy Reporter Junho Hwang] Celltrion announced on the 17th that it has signed a supply contract for Truxima, a biosimilar antibody drug, worth 21 billion KRW with Celltrion Healthcare. The contract amount corresponds to 1.86% of recent sales. The contract period is until the 19th of this month.
Hot Picks Today
"Buy on Black Monday"... Japan's Nomura Forecasts 590,000 for Samsung, 4 Million for SK hynix
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- "We're Now Earning 10 Million Won a Month"... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- Trump Warns Iran: "Nothing Will Be Left If They Don't Act Quickly"
- Experts Are Already Watching Closely..."Target Stock Price 970,000 Won" Now Only the Uptrend Remains [Weekend Money]
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
